{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation.","groups":[{"description":"Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.","id":"OG000","title":"Participants With Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"Intent to treat population includes participants who received plerixafor, underwent transplantation, and were evaluable 12 months post transplant.","reportingStatus":"POSTED","timeFrame":"Approximately month 13","title":"Number of Participants With a Durable Graft at 12 Months Post Transplantation","type":"SECONDARY","unitOfMeasure":"participants"}